Company Profile

Omega Liquidating, Inc., formerly Omega Therapeutics, Inc., was a clinical-stage biotechnology company, which was engaged in the development of a programmable epigenomic mRNA medicine to treat or cure a broad range of diseases. The Company has filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code. The Company remains in possession of its assets and continues to operate its business as a debtor in possession.

Employees

Sector

Investment Holding Companies

More about the company

08/08/25	Omega Therapeutics, Inc. Went Out of Business	CI
31/07/25	Revised Combined Liquidation Plan and Disclosure Statement Approved for Omega Therapeutics, Inc.	CI
07/07/25	First Motion for Exclusivity Period Extension Approved For Omega Therapeutics, Inc.	CI
13/06/25	Modified Disclosure Statement and Liquidation Plan Approved on an Interim Basis for Omega Therapeutics, Inc.	CI
09/06/25	First Motion for Exclusivity Period Extension Filed by Omega Therapeutics, Inc.	CI
27/05/25	Combined Liquidation Plan and Disclosure Statement Filed by Omega Therapeutics, Inc.	CI
25/04/25	Revised Stalking Horse APA	CI
23/04/25	Motion for Asset Sale Filed by Omega Therapeutics, Inc.	CI
04/04/25	Notice of Cancellation of auction	CI
12/03/25	Bidding Procedure Approved for Omega Therapeutics, Inc.	CI
12/03/25	Final DIP Financing Approved for Omega Therapeutics, Inc.	CI
24/02/25	Omega Therapeutics, Inc.(OTCPK:OMGA.Q) dropped from NASDAQ Composite Index	CI
24/02/25	Omega Therapeutics, Inc.(NasdaqGS:OMGA) dropped from S&P TMI Index	CI

15/11/24	Raymond James Downgrades Omega Therapeutics to Market Perform From Outperform	MT
07/08/24	Chardan Adjusts Price Target on Omega Therapeutics to $7 From $6, Maintains Buy Rating	MT
18/06/24	Raymond James Initiates Omega Therapeutics at Outperform Rating With $12 Price Target	MT
03/04/24	Piper Sandler Trims Price Target on Omega Therapeutics to $9 From $10, Maintains Overweight Rating	MT
01/04/24	Chardan Cuts Price Target on Omega Therapeutics to $7 From $12, Keeps Buy Rating	MT

21/11/24	Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies	AQ
15/11/24	Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results	GL
15/10/24	Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings	AQ
15/10/24	Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings	GL
27/09/24	Flagship Pioneering Unveils Mirai Bio to Provide Fully Integrated End-to-End Genetic Medicine Development Capabilities for the Biotech Industry	AQ

04/01/24	Novo Nordisk signe des partenariats de recherche avec des biotechs américaines
04/01/24	Novo Nordisk : accords de recherche avec Omega et Cellarity

3 years	0		6.3
5 years	0		31.41
10 years	0		31.41

OMEA THER Stock

Stocks

OMGA

US68217N1054

Investment Holding Companies

Latest news: OMEA THER

Analysts' recommendations: OMEA THER

Press Releases: OMEA THER

News in other languages: OMEA THER

Quotes and Performance

Price Extremes

Managers and Directors: OMEA THER

Latest insider transactions

Shell Companies

Company Profile

Manager	Title	Age	Since
Kaan Certel CEO	Chief Executive Officer	56	14/11/2024
Barbara Chan DFI	Director of Finance/CFO	62	31/05/2024
Jennifer Nelson CTO	Chief Tech/Sci/R&D Officer	-	14/08/2024

Director	Title	Age	Since
Elliott Levy BRD	Director/Board Member	67	01/03/2021
Rainer Boehm BRD	Director/Board Member	65	01/09/2022
Kaan Certel BRD	Director/Board Member	56	14/11/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/3/24 A	Ravi Mehrotra	Free	Director	50,000	0.0903%
11/22/24 A	Jennifer Nelson	Other	Chief Technology Officer	110,000	0.1994%
11/22/24 A	Jennifer Nelson	Free	Chief Technology Officer	110,000	0.1994%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OMEA THER	+50.00%	-.--%	-	-	166K
INVESTOR AB	-0.14%	+3.15%	+33.73%	+106.76%	132B
INDUSTRIVÄRDEN AB	-0.57%	+3.26%	+31.88%	+81.12%	22.89B
HAL TRUST	+0.12%	+1.80%	+24.82%	+59.77%	17.14B
MERITZ FINANCIAL GROUP INC.	+1.37%	+4.23%	+20.54%	+165.34%	16.07B
LUNDBERG B	-0.51%	+3.19%	+14.34%	+28.00%	14.69B
INVESTMENT AB LATOUR	+0.05%	+4.09%	-10.95%	+12.22%	14.08B
WASHINGTON H. SOUL PATTINSON AND COMPANY LIMITED	+0.39%	-0.93%	+21.73%	+36.95%	12.22B
BAJAJ HOLDINGS & INVESTMENT LIMITED	+0.69%	-8.54%	-16.96%	+47.79%	11.98B
KINGDOM HOLDING COMPANY	-5.03%	-6.75%	+46.19%	+59.80%	11.78B
Average	+4.64%	+1.18%	+18.37%	+66.42%	28.11B
Weighted average by Cap.	-0.24%	+2.35%	+26.11%	+86.79%